Vor BiopharmaVOR
VOR
About: Vor Biopharma Inc is a clinical stage cell therapy company. It combines a novel patient engineering approach with targeted therapies to provide a solution for patients suffering from hematological malignancies. The company's products include VOR33.
Employees: 168
0
Funds holding %
of 6,823 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)
0% more funds holding in top 10
Funds holding in top 10: 1 [Q2] → 1 (+0) [Q3]
10.19% less ownership
Funds ownership: 80.14% [Q2] → 69.95% (-10.19%) [Q3]
24% less funds holding
Funds holding: 71 [Q2] → 54 (-17) [Q3]
39% less capital invested
Capital invested by funds: $54.7M [Q2] → $33.5M (-$21.2M) [Q3]
58% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 19
62% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 26
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$12
782%
upside
Avg. target
$14.50
966%
upside
High target
$17.50
1,187%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Swayampakula Ramakanth 31% 1-year accuracy 58 / 186 met price target | 1,187%upside $17.50 | Buy Reiterated | 10 Dec 2024 |
JMP Securities Silvan Tuerkcan 29% 1-year accuracy 16 / 56 met price target | 782%upside $12 | Market Outperform Reiterated | 10 Dec 2024 |
Baird Jack Allen 33% 1-year accuracy 3 / 9 met price target | 929%upside $14 | Outperform Maintained | 8 Nov 2024 |
Financial journalist opinion
Neutral
GlobeNewsWire
1 week ago
Vor Bio Appoints Life Sciences and Technology Investor and Entrepreneur, Mr. Erez Kalir to its Board of Directors
CAMBRIDGE, Mass., Jan. 08, 2025 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Mr. Erez Kalir to its Board of Directors. The appointment represents a new seat on Vor Bio's Board of Directors, which has been created in connection with the recent private investment in public equity financing (PIPE) which was led by Reid Hoffman. Mr. Kalir will serve as the director designee of Reprogrammed Interchange, LLC, Mr. Hoffman's investment fund.
Neutral
GlobeNewsWire
3 weeks ago
Vor Bio Announces $55.6 Million Private Placement
Intend to announce updated clinical data from Phase 1/2 VBP301 trial of VCAR33 ALLO in the first half of 2025 and updated clinical data from Phase 1/2a VBP101 trial of trem-cel in combination with Mylotarg in the second half of 2025
Neutral
GlobeNewsWire
1 month ago
Vor Bio Provides Clinical Update Further Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies; Receives Supportive Feedback from FDA Regarding Registrational Trial Design
CAMBRIDGE, Mass., Dec. 09, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced updated clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed/refractory AML receiving trem-cel followed by Mylotarg™. The data, which was presented in a poster at the American Society of Hematology (ASH) Annual Meeting on Sunday, December 8th, demonstrated durable engraftment, shielding from Mylotarg on-target toxicity, a broadened Mylotarg therapeutic window, and early evidence of improved relapse free survival compared to published high-risk AML comparators.
Neutral
GlobeNewsWire
3 months ago
Vor Bio Appoints Seasoned Healthcare Institutional Investor, Han Choi, M.D., LL.M., as Chief Financial Officer
CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Han Choi, M.D., LL.M., as its new Chief Financial Officer, effective immediately. Dr. Choi will join the Vor Bio leadership team and will report directly to the company's President and Chief Executive Officer, Dr. Robert Ang.
Positive
Benzinga
4 months ago
What's Going On With Penny Stock Blood Cancer-Focused Vor Biopharma On Friday?
Thursday, Vor Biopharma Inc. VOR announced new clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed/refractory acute myeloid leukemia (AML) receiving trem-cel followed by Mylotarg.
Neutral
GlobeNewsWire
4 months ago
New Clinical Data Validates Vor Bio's Approach of Using Shielded Transplants to Deliver Targeted Therapies
CAMBRIDGE, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced new clinical data from its ongoing Phase 1/2 VBP101 study of patients with relapsed/refractory AML receiving trem-cel followed by Mylotarg™. The data demonstrated reliable engraftment, shielding from Mylotarg on-target toxicity, a broadened Mylotarg therapeutic window, and early evidence of patient benefit.
Neutral
GlobeNewsWire
4 months ago
Vor Bio to Participate in Upcoming Investor Conferences
CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming investor conferences:
Neutral
GlobeNewsWire
5 months ago
Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update
CAMBRIDGE, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today reported financial results for the three-month period ended June 30, 2024, and provided a corporate update.
Neutral
GlobeNewsWire
5 months ago
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., Aug. 02, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of July 31, 2024, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 1,250 shares of Vor Bio's common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 1,875 shares of Vor Bio's common stock to one newly hired employee. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).
Neutral
GlobeNewsWire
6 months ago
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of July 1, 2024, the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 3,000 shares of Vor Bio's common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 4,500 shares of Vor Bio's common stock to three newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).
Charts implemented using Lightweight Charts™